Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

Submitted by admin on May 5, 2024 - 11:40pm
Source: 
Motley Fool
News Tags: 
Prizer
danuglipron
obesity
Eli Lilly
Novo Nordisk
Headline: 
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
snippet: 
  • The outlook for Pfizer's experimental obesity drug danuglipron is murky at best.
  • Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.
  • Still, Pfizer appears to be committed to carving out a stake in the huge obesity market.

Do Not Allow Advertisers to Use My Personal information